Full history for every metric is available with a Kvantra account
ISR Immune System Regulation Holding AB (publ) (ISR.ST)
Key financial summary
Financials in SEK| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | SEK m | -79 | -21 | |||||
| Net profit | SEK m | -6 | -21 | -21 | -29 | -32 | -79 | -21 |
| EPS reported | SEK | -1.14 | -0.97 | |||||
| Operating cashflow per share | SEK | -0.98 | -0.98 | |||||
| Capex per share | SEK | 0.00 | 0.00 | |||||
| FCF per share | SEK | -0.98 | -0.98 | |||||
| Free cash flow | SEK m | -67 | -21 | |||||
| Net debt | SEK m | -54 | -1 | |||||
| Book value equity | SEK m | 39 | -165 | |||||
| Book value per share | SEK | 0.56 | -6.85 | |||||
| Number of shares | m | 69.01 | 24.02 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 16.48 | -0.59 | |||||
| P/S LTM | x | 0.00 | 1,857.93 | |||||
| P/FCF LTM | x | -9.42 | -4.60 | |||||
| EV/EBITDA LTM | x | -7.42 | -4.66 | |||||
| EV/Sales LTM | x | 0.00 | 1,831.30 | |||||
| Earnings Yield LTM | % | -12.38% | -81.38% | |||||
| FCF Yield | % | -10.62% | -21.73% | |||||
| Quality | ||||||||
| ROE | % | -204.02% | -211.70% | |||||
| ROIC | % | -198.76% | -198.76% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.69 | 0.69 | |||||
| EBIT/Net interest | x | -13,101.50 | -13,101.50 | |||||
| Net debt/market cap | % | -8.47% | -1.43% | |||||
| Net debt/Equity | x | -1.39 | 0.01 | |||||
| Gross debt/equity | x | 0.00 | -0.00 | |||||
Company overview
ISR Immune System Regulation Holding AB (publ), headquartered in Stockholm, Sweden, is dedicated to the discovery and development of pharmaceutical solutions for viral infections. Its current therapeutic pipeline features a Covid-19 vaccine candidate, treatments for Hepatitis B (HBV) and HIV, and an oncology program.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ISR Immune System Regulation Holding AB (publ) (ISR.ST)
ISR Immune System Regulation Holding AB (publ), headquartered in Stockholm, Sweden, is dedicated to the discovery and development of pharmaceutical solutions for viral infections. Its current therapeutic pipeline features a Covid-19 vaccine candidate, treatments for Hepatitis B (HBV) and HIV, and an oncology program.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free